首页> 外文期刊>JAMA: the Journal of the American Medical Association >Changes in direct-to-consumer pharmaceutical advertising following shifts from prescription-only to over-the-counter status
【24h】

Changes in direct-to-consumer pharmaceutical advertising following shifts from prescription-only to over-the-counter status

机译:从仅处方药转变为非处方药后,直接面向消费者的药品广告的变化

获取原文
获取原文并翻译 | 示例
       

摘要

Direct-to-consumer advertising (DTCA) can influence the use of prescription drugs.1-2 The US Food and Drug Administration (FDA) regulates prescription drug advertising, including requirements to provide consumers with a "fair balance" of risks and benefits. When prescription drugs switch to over-the-counter (OTC) status, regulatory oversight of their advertising shifts to the Federal Trade Commission (FTC). Unlike the FDA, the FTC holds drug advertisements to the same standards as any consumer product: it applies a "reasonable consumer" standard of truthfulness and nondeception that does not require any balancing of potential benefits and harms. Such a shift may be associated with changes in content.
机译:直接面向消费者的广告(DTCA)可能会影响处方药的使用。1-2美国食品和药物管理局(FDA)对处方药广告进行监管,包括要求为消费者提供风险和收益的“公平平衡”。当处方药转换为非处方药(OTC)状态时,对其广告的监管将转移到联邦贸易委员会(FTC)。与FDA不同,FTC按照与任何消费产品相同的标准来宣传药品广告:它采用了“合理的消费者”真实性和非欺骗性标准,不需要对潜在的利益和危害进行任何平衡。这样的转变可以与内容的改变相关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号